TRACON Pharmaceuticals, Inc. Announces TRC105 Clinical Trials, Abstract Presentations at 2013 American Society of Clinical Oncology Annual Meeting
5/20/2013 6:47:46 AM
More...
|
TRACON Pharmaceuticals, Inc. Announces Appointment of Kenneth Galbraith as Chairman of the Board
12/6/2011 10:07:42 AM
More...
|
TRACON Pharmaceuticals, Inc. Announces $22 Million Tranched Investment Led by JAFCO and Nextech to Fund TRC105 Phase 2 Development
4/20/2011 6:50:10 AM
More...
|
TRACON Pharmaceuticals, Inc. Announces Upcoming Scientific Presentations on Clinical-Stage Cancer Therapeutics TRC105 and TRC102
10/25/2010 9:15:56 AM
More...
|
TRACON Pharmaceuticals, Inc. to Present Three First-in-Class Oncology Therapeutics (TRC105, TRC102, and TRC093) at the American Society of Clinical Oncology 2010 Annual Meeting
5/19/2010 8:30:54 AM
More...
|
TRACON Pharmaceuticals, Inc. Announces Start of Phase 1/2 Trial of TRC105 Antibody Therapy for Prostate Cancer
4/26/2010 9:00:53 AM
More...
|
Formatech, Inc. Donates Services to Formulate and Fill TRACON Pharmaceuticals, Inc.'s TRC102 Compound under Its "Fillanthropy(TM) Program"
3/22/2010 9:16:32 AM
More...
|
TRACON Pharmaceuticals, Inc. Announces CRADA With National Cancer Institute to Study TRC105 in Prostate Cancer
10/19/2009 8:33:18 AM
More...
|
TRACON Pharmaceuticals, Inc.'s Small Molecule TRC102 and Antibody TRC105 to be Presented at American Society of Clinical Oncology 2009
5/26/2009 8:43:03 AM
More...
|
TRACON Pharmaceuticals, Inc. to Present Clinical Stage Programs at AACR 2009
2/17/2009 10:13:49 AM
More...
|
|